Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.

Alimentary pharmacology & therapeutics - 15 Oct 2008

Ansari A, Arenas M, Greenfield S M, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J

Abstract excerpt

AIM: To investigate whether pharmacogenetic loci or metabolite concentrations explain clinical response or side effects to AZA. METHODS: Patients with IBD were given 2 mg/kg of AZA without dose escalation or adjustment. Serial clinical response, thiopurine methyl transferase (TPMT) activity and thioguanine nucleotide (TGN) concentrations were measured over 6 months. All patients were genotyped for inosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Azathioprine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Inflammatory Bowel Diseases

Share to Methyltransferases

Share to Predictive Value of Tests

Share to Thionucleotides

Share to Young Adult

Source

Identifiers

PMID: 18616518
DOI: 10.1111/j.1365-2036.2008.03788.x

Genes

TPMT
ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.PMID 18616518Read ↗

A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.Semantic proximity Read ↗

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Semantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.Semantic proximity Read ↗

The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.Semantic proximity Read ↗

Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).Semantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.Semantic proximity Read ↗

On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.Semantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease.Semantic proximity Read ↗

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.Semantic proximity Read ↗

Pharmacogenetics in inflammatory bowel diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.